City Therapeutics appoints Andrew Orth as CEO, leveraging his expertise in RNA and gene therapies as the company advances its ...

INmune Bio’s (INMB) treatment of epidermolysis bullosa received FDA orphan designation, according to a post on the agency’s site.Don't Miss Our ...

Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label StudyDemonstrated Clinical ...

AGLE-102 is under clinical development by Aegle Therapeutics and currently in Phase II for Epidermolysis Bullosa.

The Penguin star joined 22,000 runners in the 26.2 mile race, where he raised money for his friend Emma Fogarty. She has a ...

CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABEO) today announced it has granted equity awards to new ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

From the death of former taoiseach John Bruton, to the unexpected resignation of Leo Varadkar as premier, the year has been ...

The agreement involves the sale of certain assets, including intellectual property rights and royalty rights, related to FCX-007, a clinical stage product candidate developed by Castle Creek ...

Go watch the Sisyphus video if you haven’t already. Goosebumps.

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales, doubling from Q4 2023. Trading at 57x 2024 earnings, Krystal's stock appears expensive but is ...

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.